Finance

Lists
INBX:NASDAQ
Inhibrx Biosciences Inc
US$101,38
+1,29%
(+1,29) 1D
1 āš•.āšĨ., 10 āŧ‚āšĄāš‡ 16 āš™āšēāš—āšĩ 28 āš§āšīāš™āšēāš—āšĩ GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for INBX...
Open
US$100,71
High
US$102,16
Low
US$99,49
Mkt. cap
1,49Â āš•āš·āŧ‰
Avg. vol.
348,02Â āšžāšąāš™
Volume
38,84Â āšžāšąāš™
52-wk high
US$155,29
52-wk low
US$28,16
EPS
US$-8,88
Shares outstanding
14,72 āšĨāŧ‰āšēāš™
No. of employees
110
Open
US$100,71
High
US$102,16
Low
US$99,49
Mkt. cap
1,49Â āš•āš·āŧ‰
Avg. vol.
348,02Â āšžāšąāš™
Volume
38,84Â āšžāšąāš™
52-wk high
US$155,29
52-wk low
US$28,16
EPS
US$-8,88
Shares outstanding
14,72 āšĨāŧ‰āšēāš™
No. of employees
110
News stories
From web sources and news partners
About Inhibrx Biosciences Inc
CEO-
Employees110
Founded2024
HeadquartersLa Jolla, āŧāš„āšĨāšīāšŸāŧāŧ€āš™āš, āšŠāš°āšŦāš°āšĨāšąāš”
SectorBiotechnology
Analyst ratings
Based on 3 analysts giving stock ratings to INBX in the past 3 months
Strong buy
Buy
3
Hold
0
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for INBX in the last 3 months.
Highest
Current US$101,38
US$325,00 (+220,59%)
Average
US$266,67 (+163,05%)
Lowest
US$230,00 (+126,88%)
Analyst
Recommendation
Action
Price target
Projected
Date
Robert Burns
H.C. Wainwright
Buy
Reiterated
US$245,00
+141,7%
09/09/2026
Oliver McCammon
LifeSci Capital
Buy
Maintained
US$230,00
+126,9%
09/08/2026
Dara Azar
Stifel Nicolaus
Buy
Maintained
US$325,00
+220,6%
08/21/2026
Unknown Analyst
Stifel Nicolaus
Buy
Initiated
US$150,00
+48%
04/08/2026
Last report
13 āšŠ.āšŦ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
US$-2,34 / US$-1,34
-74,63%miss
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
āš.āš. 2025
āš—.āš§. 2025
āšĄ.āš™. 2026
āšĄāšī.āš–. 2026
Revenue
-
-
-
-
Cost of goods sold
28,54 āšĨāŧ‰āšēāš™
25,35 āšĨāŧ‰āšēāš™
25,22 āšĨāŧ‰āšēāš™
23,90 āšĨāŧ‰āšēāš™
Cost of revenue
28,54 āšĨāŧ‰āšēāš™
25,35 āšĨāŧ‰āšēāš™
25,22 āšĨāŧ‰āšēāš™
23,90 āšĨāŧ‰āšēāš™
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5,28 āšĨāŧ‰āšēāš™
5,57 āšĨāŧ‰āšēāš™
5,71 āšĨāŧ‰āšēāš™
8,25 āšĨāŧ‰āšēāš™
Operating expense
5,28 āšĨāŧ‰āšēāš™
5,57 āšĨāŧ‰āšēāš™
5,71 āšĨāŧ‰āšēāš™
8,25 āšĨāŧ‰āšēāš™
Total operating expenses
33,81 āšĨāŧ‰āšēāš™
30,92 āšĨāŧ‰āšēāš™
30,93 āšĨāŧ‰āšēāš™
32,15 āšĨāŧ‰āšēāš™
Operating income
-33,81 āšĨāŧ‰āšēāš™
-30,92 āšĨāŧ‰āšēāš™
-30,93 āšĨāŧ‰āšēāš™
-32,15 āšĨāŧ‰āšēāš™
Other non operating income
-46,00Â āšžāšąāš™
-39,00Â āšžāšąāš™
-12,00Â āšžāšąāš™
-68,00Â āšžāšąāš™
EBT including unusual items
-35,26 āšĨāŧ‰āšēāš™
-32,83 āšĨāŧ‰āšēāš™
-33,44 āšĨāŧ‰āšēāš™
-36,65 āšĨāŧ‰āšēāš™
EBT excluding unusual items
-35,26 āšĨāŧ‰āšēāš™
-32,83 āšĨāŧ‰āšēāš™
-33,44 āšĨāŧ‰āšēāš™
-36,65 āšĨāŧ‰āšēāš™
Income tax expense
-
-
-
3,00Â āšžāšąāš™
Effective tax rate
-
-
-
-0,01%
Other operating expenses
-
-
-
-
Net income
-35,26 āšĨāŧ‰āšēāš™
-32,83 āšĨāŧ‰āšēāš™
-33,44 āšĨāŧ‰āšēāš™
-36,65 āšĨāŧ‰āšēāš™
Net profit margin
-
-
-
-
Earnings per share
-2,28
-2,11
-2,15
-2,34
Interest and investment income
1,78 āšĨāŧ‰āšēāš™
1,31 āšĨāŧ‰āšēāš™
1,01 āšĨāŧ‰āšēāš™
1,26 āšĨāŧ‰āšēāš™
Interest expense
-3,18 āšĨāŧ‰āšēāš™
-3,18 āšĨāŧ‰āšēāš™
-3,51 āšĨāŧ‰āšēāš™
-5,69 āšĨāŧ‰āšēāš™
Net interest expenses
-1,40 āšĨāŧ‰āšēāš™
-1,87 āšĨāŧ‰āšēāš™
-2,50 āšĨāŧ‰āšēāš™
-4,43 āšĨāŧ‰āšēāš™
Depreciation and amortization charges
-
-
-
-
EBITDA
-33,23 āšĨāŧ‰āšēāš™
-30,36 āšĨāŧ‰āšēāš™
-30,39 āšĨāŧ‰āšēāš™
-31,63 āšĨāŧ‰āšēāš™
Gain or loss from assets sale
3,00Â āšžāšąāš™
9,00Â āšžāšąāš™
-
14,00Â āšžāšąāš™
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
āŧāš­āšąāššāš‚āš­āš‡ Google